CJC 1295 with DAC CD2 2mg*10vials

CJC 1295 DAC CD2 (2mg x 10 vials) is a high-purity, long-acting growth hormone-releasing hormone (GHRH) analog research peptide, a low-dose, stable version of the upgraded CD series. CD2 utilizes specialized DAC (drug affinity complex) albumin-binding modification technology, effectively resisting DPP-IV enzyme degradation and renal clearance, achieving an ultra-long circulating half-life of 6-8 days, significantly different from common short-acting GHRH peptides. Its precise 2mg dosage is designed for fine-dose gradient screening, long-term low-frequency GH/IGF-1 axis intervention, chronic endocrine remodeling studies, and biosafety and tolerability validation. As a core, long-acting metabolic peptide in growth hormone peptide drugs, CJC 1295 DAC CD2 is widely used in preclinical studies of body composition regulation, age-related endocrine function decline, and tissue anabolic mechanisms.

Product Functions and Research Value

Laboratory studies have shown that CJC 1295 DAC CD2 can stably stimulate pituitary growth hormone secretion and continuously upregulate IGF-1 expression in the liver and peripheral tissues, thereby maintaining a long-term, low-fluctuation activation state of the growth hormone axis. Due to its unique albumin-binding properties, a single intervention can provide several days of sustained, mild physiological signal stimulation, avoiding the drastic fluctuations in hormone levels seen with common short-acting peptide drugs. Its core research directions include mildly promoting lean tissue anabolism, stably regulating lipid metabolism, promoting collagen synthesis and connective tissue repair, and long-term improvement of age-related endocrine dysfunction. The low-dose CD2 version has mild efficacy, excellent model tolerability, and extremely low stress interference, making it an ideal choice for long-term chronic mechanism studies, slow metabolic remodeling modeling, and exploring low-threshold dose-response relationships. It can provide highly stable and reproducible baseline experimental data for GH/IGF-1 axis studies.

Core Product Advantages

1. Stable CD2-Based Iteration: Based on optimized modifications of the classic CJC 1295 DAC, it boasts purer molecular activity and lower non-specific binding. It retains its complete long-acting endocrine properties, providing a milder and more stable experimental phenotype, suitable for basic exploratory research.

2. Ultra-Long-Acting DAC Core Technology: Professional drug affinity complex modification enables stable binding to serum albumin, resists enzymatic degradation, and significantly prolongs the duration of action in vivo. It supports low-frequency dosing and long-term continuous intervention, greatly simplifying long-term experimental protocols.

3. Precise 2mg Low-Dose Specification: An exclusive entry-level low-concentration design fills the gap in low-dose long-acting GHRH research. Effectively avoids physiological stress and GH axis desensitization caused by high-dose shocks, perfectly suited for biosafety testing and fine gradient grouping experiments.

4. Highly Selective Endocrine Regulation: Precisely activates downstream GHRH pathways, stably increasing GH and IGF-1 levels, with no significant interference with cortisol, prolactin, and other stress hormones, ensuring ultra-pure experimental variables. 5. Pharmaceutical-grade quality and standard packaging: Aseptic vacuum freeze-drying process locks in all peptide activity. Each batch undergoes rigorous HPLC purity testing and comes with a complete Certificate of Account (COA). Each box contains 10 vials in integrated packaging, meeting the needs of routine laboratory basic research, university endocrinology projects, and bulk wholesale purchases.

CJC 1295 DAC CD2 2mg*10 vials is a high-purity, long-acting growth hormone-releasing hormone (GHRH) analog research peptide, a basic low-dose stable version of the CD iterative series. Utilizing a special DAC drug affinity compound modification technology, it effectively resists DPP-IV enzyme degradation and renal metabolic clearance, resulting in a long in vivo half-life of 6-8 days, significantly different from ordinary short-acting GHRH peptides. Its precisely formulated 2mg low-dose specification is suitable for fine-dose gradient screening, long-term low-frequency GH/IGF-1 axis intervention, chronic endocrine remodeling studies, and biosafety and tolerability verification. It is a core research component of growth hormone peptide drugs, focusing on long-term homeostasis regulation and widely used in preclinical and basic research on body composition regulation, age-related endocrine decline, and tissue anabolic mechanisms.

Core uses and research value of peptide drugs: In research settings, CJC 1295 DAC CD2 can stably stimulate pituitary growth hormone secretion and exert its effects continuously.